Osteoporosis News and Research

Latest Osteoporosis News and Research

Asahi Kasei announces commencement of tender offer for ZOLL

Asahi Kasei Corporation, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, announced today the commencement of a tender offer through its indirect wholly owned U.S. subsidiary Asclepius Subsidiary Corporation for all outstanding shares of common stock of ZOLL Medical Corporation for $93 per share, net to the seller in cash, without interest and less any required withholding taxes.

26 Mar 2012

Osteoporosis researcher receives IOF Medal of Achievement

Today, at the European Congress on Osteoporosis & Osteoarthritis, Professor Cyrus Cooper was awarded the International Osteoporosis Foundation (IOF) Medal of Achievement.

26 Mar 2012

$Large geographic variation in risk of hip fracture$

Large geographic variation in risk of hip fracture

An extensive study of country-specific risk of hip fracture and 10-year probability of a major fragility fracture has revealed a remarkably large geographic variation in fracture risk. Even accounting for possible errors or limitations in the source data, there was an astonishing 10-fold variation in hip fracture risk and fracture probability between countries.

22 Mar 2012

FDA approves Watson's generic BONIVA ANDA to treat osteoporosis in women

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc. has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Ibandronate 150mg tablets, the generic equivalent to Roche's BONIVA tablets.

21 Mar 2012

Mylan receives final FDA approval for generic Boniva ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ibandronate Sodium Tablets, 150mg.

20 Mar 2012

Tarsa advances OSTORA NDA filing through $28M Series B financing

Tarsa Therapeutics, Inc. today announced completion of a $28 million Series B equity financing led by new investor Foresite Capital.

17 Mar 2012

New UCLA Alzheimer's and Dementia Care program for patients, caregivers

Alzheimer's disease affects an estimated 5.4 million people in the U.S., some 480,000 of them in California. Nearly half of all people 85 and older will be stricken with the disease. The overall burden of dementia is still higher, with Alzheimer's accounting for only 60 to 80 percent of dementia cases.

15 Mar 2012

EffRx receives FDA approval for BINOSTO to treat osteoporosis

EffRx Pharmaceuticals SA today announced that the U.S. Food and Drug Administration (FDA) has approved BINOSTO (alendronate sodium) Effervescent Tablets, previously known as EX101, for the treatment of osteoporosis in postmenopausal women, and as a treatment to increase bone mass in men with osteoporosis. EffRx anticipates that BINOSTO will be commercially available in the United States in the third quarter of 2012.

15 Mar 2012

Highlights from Journal of the American Academy of Orthopaedic Surgeons

The Spine Patient Outcomes Research Trial (SPORT) is the first comprehensive study to look at the effectiveness of different treatments for low back and leg pain. It was designed to provide data and outcomes to guide doctors and their patients in their treatment choices for three common spinal disorders: intervertebral disk herniation (IDH), degenerative spondylolisthesis (DS), and lumbar spinal stenosis (LSS).

14 Mar 2012

Asahi Kasei to acquire ZOLL

Asahi Kasei Corporation, and ZOLL Medical Corporation today jointly announced that Asahi Kasei, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, has entered into a definitive merger agreement with ZOLL, a manufacturer of resuscitation and critical care devices and related software solutions, pursuant to which Asahi Kasei will acquire ZOLL for approximately $2.21 billion.

12 Mar 2012

Concerns about aging in good health

Do men harbour concerns about aging in good health? Do they confide these concerns to their physicians? Are men's concerns the same as women's? The answers to these questions can be found in a large cross-sectional survey of 2325 Canadian men, aged 55 to 97 years old, led by Dr. Cara Tannenbaum, Geriatrician and the Michel Saucier Endowed Chair in Geriatric Pharmacology, Health and Aging at the Institut universitaire de gériatrie de Montréal (IUGM) which is affiliated with the Université de Montréal.

10 Mar 2012

Unigene fourth quarter net income increases to $4.4 million

Unigene Laboratories, Inc., today announced financial results for the fourth quarter and full-year ended December 31, 2011.

9 Mar 2012

New ultrasound technique for rapid and accurate assessment of osteoporosis

Laser-based measurements are proving to be a promising method for the assessment of osteoporosis. The team led by Professor Jussi Timonen has developed an ultrasound technique that use laser beams for a rapid and accurate assessment of osteoporosis.

8 Mar 2012

$Vitamin D in pre-teen girls protects from stress fractures and bone injuries: Study$

Vitamin D in pre-teen girls protects from stress fractures and bone injuries: Study

A new study shows that girls and young women who got lots of vitamin D through their diet and supplements were half as likely to suffer a stress fracture as those who didn't.

5 Mar 2012

Pre-registration deadline for European Congress on Osteoporosis & Osteoarthritis

Join the IOF and ESCEO in Bordeaux, France for Europe's premier bone event.

5 Mar 2012

Vitamin E may lead to thinning and weakening of bones: Study

From studies in laboratory animals it was found that the most common form of vitamin E stimulates the generation of bone-degrading cells. Scientists who carried out the research in Japan are now calling for their results to be followed up in humans.

4 Mar 2012

Bisphosphonates improve fixation of dental impants in human bones

Millions of people have bad teeth replaced with implants. Often following the procedure, they are unable to chew food for up to six months, until the implant has become fixated in the bone. Now, for the first time, a drug coating that has been tested on humans allows titanium screws to adhere to the bone better and faster. The Link-ping researchers behind the method report that the results are good.

2 Mar 2012

$DXA scan should be done at shorter intervals for women at high risk for fracture$

DXA scan should be done at shorter intervals for women at high risk for fracture

Although a recent study suggests that women with normal results on dual-energy X-ray absorptiometry (DXA) scans at ages 67 and older may wait up to 15 years for a second test, a Viewpoint article published today in the Journal of Bone and Mineral Research (JBMR) cautions that such a lengthy interval is inappropriate for many adults.

2 Mar 2012

NexGen receives U.S. patent allowance for novel pathogenesis based seizure treatment

NexGen Biomedical, Inc.'s Founder has received a Notice of Allowance from the US Patent Office for a novel treatment method for seizures.

2 Mar 2012

Maturitas publishes EMAS' clinical guide on SERMs against postmenopausal osteoporosis

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of an important clinical guide from the European Menopause and Andropause Society (EMAS) in the February issue of Maturitas.

29 Feb 2012